US Food and Drug Administration Approval Summary: Elacestrant for Estrogen Receptor–Positive, Human Epidermal Growth Factor Receptor 2–Negative, ESR1-Mutated Advanced or Metastatic Breast Cancer

发表于 2026-7-15 13:15:06

期刊：Journal of Clinical Oncology

文献作者：Mirat Shah; Hima Lingam; Xin Gao; Haley Gittleman; Mallorie H. Fiero; Danielle Krol; Nikolett Biel; Tiffany K. Ricks; Wentao Fu; Salaheldin Hamed; Fang Li; Jillian (Jielin) Sun; Jianghong Fan; Robert Schuck; Manuela Grimstein; Liuya Tang; Shyam Kalavar; Abdelrahmman Abukhdeir; Anand Pathak; Soma Ghosh; Ilynn Bulatao; Amy Tilley; William F. Pierce; Bronwyn D. Mixter; Shenghui Tang; Richard Pazdur; Paul Kluetz; Laleh Amiri-Kordestani

出版日期：2024-4-1

DOI号：10.1200/jco.23.02112

下载链接：https://ascopubs.org/doi/pdfdirect/10.1200/JCO.23.02112

文献链接：https://doi.org/10.1200/jco.23.02112

当前文献来源于 American Society of Clinical Oncology (ASCO)。

备注信息：

发表于 2026-7-15 13:15:07

: 当前求助已完成，请重新发起求助。
已完结状态的附件将会在24小时内删除。

[ASCO] US Food and Drug Administration Approval Summary: Elacestrant for Estrogen Receptor–Positive, Human Epidermal Growth Factor Receptor 2–Negative, ESR1-Mutated Advanced or Metastatic Breast Cancer

已采纳

同分类求助

最新回复

站点公告

今日热心研友

（热心研友QQ群）

[ASCO] US Food and Drug Administration Approval Summary: Elacestrant for Estrogen Receptor–Positive, Human Epidermal Growth Factor Receptor 2–Negative, ESR1-Mutated Advanced or Metastatic Breast Cancer 一键复制